Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995352 | 0.88 | NR1H2 (0.48) | KIF11NR1H2NR1H3PTGDR2BRD4 | |
| SCHEMBL1190580 | 0.88 | KIF11 (0.47) | KIF11NR1H2NR1H3PTGDR2PTGS2 | |
| SCHEMBL1191536 | 0.86 | KIF11 (0.46) | KIF11NR1H2NR1H3PTGDR2PTGS2 | |
| SCHEMBL31716134 | 0.86 | KIF11 (0.46) | KIF11NR1H2NR1H3PTGDR2PTGS2 | |
| SCHEMBL3710331 | 0.86 | KIF11 (0.46) | KIF11NR1H2NR1H3PTGDR2PTGS2 | |
| SCHEMBL12560322 | 0.86 | PTGDR2 (0.45) | KIF11NR1H2NR1H3PTGDR2FFAR4 | |
| SCHEMBL13995366 | 0.85 | KIF11 (0.43) | KIF11NR1H2NR1H3PTGDR2BRD4 | |
| SCHEMBL1762386 | 0.84 | FFAR4 (0.39) | KIF11PTGDR2FFAR4CCR2ESR1 | |
| SCHEMBL13995384 | 0.83 | KIF11 (0.44) | KIF11NR1H2NR1H3PTGDR2PTGS2 | |
| SCHEMBL14242842 | 0.79 | HTR2A (0.38) | KIF11HRH4FFAR4CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | disclosed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | disclosed |
| US-8791256-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791256-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20130267518-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130267518-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8470848-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-06-25 | — | — | US | disclosed |
| US-8455645-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20100204225-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-12 | — | — | US | disclosed |
| US-20100204225-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-12 | — | — | US | disclosed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267518-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | KIF11 4407/4885NR1H2 275/4885NR1H3 978/4885 |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | KIF11 4407/4885NR1H2 275/4885NR1H3 978/4885 |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | KIF11 3061/4885NR1H2 627/4885NR1H3 684/4885 |
| US-20100204225-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | KIF11 2549/4885NR1H2 787/4885NR1H3 575/4885 |
| US-20080312230-A1 | Organic Compounds | OPRM1, OPRL1, OPRD1 | KIF11 2889/4885NR1H2 559/4885NR1H3 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.